Paclitaxel induces apoptosis and reduces proliferation by targeting epidermal growth factor receptor signaling pathway in oral cavity squamous cell carcinoma

Hu,Jing; Zhang,Na; Wang,Ronglin; Huang,Fei; Li,Guang

doi:10.3892/ol.2015.3499

Paclitaxel induces apoptosis and reduces proliferation by targeting epidermal growth factor receptor signaling pathway in oral cavity squamous cell carcinoma

Authors:
- Jing Hu
- Na Zhang
- Ronglin Wang
- Fei Huang
- Guang Li
View Affiliations

Affiliations: Department of Stomatology, The Military General Hospital of Beijing PLA, Beijing 100700, P.R. China, Department of Stomatology, General Hospital of The Second Artillery, Beijing 100088, P.R. China, Jinan Stomatologic Hospital, Jinan, Shandong 250001, P.R. China, Department of Stomatology, Navy General Hospital, Beijing 100048, P.R. China
Published online on: July 16, 2015 https://doi.org/10.3892/ol.2015.3499
Pages: 2378-2384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral cavity cancer is common worldwide. Furthermore, the epidermal growth factor receptor (EGFR) signaling pathway is considered to be constitutively activated in oral cancers. Paclitaxel is widely accepted as an antitumor drug as it effectively inhibits the cell cycle. This study predominantly explores the possible molecule mechanism of paclitaxel on oral cancer treatment. Cell viability was first detected using an MTT assay. Cell apoptosis was examined by Hoechst staining and flow cytometry using an annexin‑V and propidium iodide kit. Specific EGFR signaling pathways were further explored through western blot analysis. Abnormal protein expression levels were determined via immunofluoresence. Additionally, the protein levels of matrix metalloproteinase (MMP)‑2 and 9 were determined using ELISA. Paclitaxel significantly inhibited oral cancer cell viability in a time‑ and dose‑dependent manner. Paclitaxel also enhanced oral cancer cell apoptosis via increased Bim and Bid protein expression. Furthermore, paclitaxel was observed to inhibit oral cancer cell proliferation through increased MMP‑2 and MMP‑9 protein levels. Paclitaxel inhibited the growth of the oral cancer cell line, tea8113 malignant proliferation and enhanced tea8113 cell apoptosis through inhibiting the EGFR signaling pathway.

View Figures

View References

1	Regezi JA, Sciubba JJ and Jordan RC: Oral Pathology: Clinical Pathologic Correlations. 6th. Elsevier Health Sciences; St. Louis, MO: 2012
2	Lookingbill DP, Spangler N and Sexton FM: Sexton: Skin involvement as the presenting sign of internal carcinoma. A retrospective study of 7316 cancer patients. J Am Acad Dermatol. 22:19–26. 1990. View Article : Google Scholar : PubMed/NCBI
3	Yin XM: Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res. 10:161–167. 2000. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
5	Petti S and Scully C: Oral cancer knowledge and awareness: primary and secondary effects of an information leaflet. Oral Oncol. 43:408–415. 2007. View Article : Google Scholar : PubMed/NCBI
6	Liu D, He J, Yuan Z, et al: EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 29:401–405. 2012. View Article : Google Scholar : PubMed/NCBI
7	Saxena R, Chandra V, Manohar M, et al: Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways. PLoS One. 8:e662462013. View Article : Google Scholar : PubMed/NCBI
8	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
9	Shen Q, Uray IP, Li Y, et al: Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 1:45–55. 2008. View Article : Google Scholar : PubMed/NCBI
10	Li Z, Zhang H, Chen Y, Fan L and Fang J: Forkhead transcription factor FOXO3a protein activates nuclear factor kappaB through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation. J Biol Chem. 287:17737–17745. 2012. View Article : Google Scholar : PubMed/NCBI
11	Wang C, Song X, Li Y, et al: Low-Dose Paclitaxel Ameliorates Pulmonary Fibrosis by Suppressing TGF-beta1/Smad3 Pathway via miR-140 Upregulation. PLoS One. 8:e707252013. View Article : Google Scholar : PubMed/NCBI
12	Li H, Duan ZW, Xie P, et al: Effects of paclitaxel on EGFR endocytic trafficking revealed using quantum dot tracking in single cells. PLoS One. 7:e454652012. View Article : Google Scholar : PubMed/NCBI
13	Guo YH, Gao FH, Shi J, Yuan HH and Jiang B: [EGFR-ERK signaling pathway down-regulates miRNA-145 in lung cancer cells]. Zhonghua Zhong Liu Za Zhi. 35:187–192. 2013.(In Chinese). PubMed/NCBI
14	Soares AS, Costa VM, Diniz C and Fresco P: Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma. Biomed Pharmacother. 67:777–789. 2013. View Article : Google Scholar : PubMed/NCBI
15	Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012. View Article : Google Scholar : PubMed/NCBI
16	Meloche S and Pouysségur J: The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 26:3227–3239. 2007. View Article : Google Scholar : PubMed/NCBI
17	Li MS, Li PF, Chen Q, Du GG and Li G: Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol. 10:819–824. 2004.PubMed/NCBI
18	Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K and Tamaki T: Antioxidants inhibit JNK and p38 MAPK activation but not ERK 1/2 activation by angiotensin II in rat aortic smooth muscle cells. Hypertens Res. 24:251–261. 2001. View Article : Google Scholar : PubMed/NCBI
20	PaezPereda M, Kuchenbauer F, Arzt E and Stalla GK: Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix. Braz J Med Biol Res. 38:1487–1494. 2005. View Article : Google Scholar : PubMed/NCBI
21	O'Connell RM and Baltimore D: MicroRNAs and hematopoietic cell development. Curr Top Dev Biol. 99:145–174. 2012. View Article : Google Scholar : PubMed/NCBI
22	Pick A and Wiese M: Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3 K/Akt signaling pathway. Chem Med Chem. 7:650–662. 2012. View Article : Google Scholar : PubMed/NCBI
23	Lee DH, Szczepanski MJ and Lee YJ: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem. 106:1113–1122. 2009. View Article : Google Scholar : PubMed/NCBI
24	Lowe VJ, Booya F, Fletcher JG, et al: Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol. 7:422–430. 2005. View Article : Google Scholar : PubMed/NCBI
25	SchwarzDose J, Untch M, Tiling R, et al: Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [¹⁸F] fluorodeoxyglucose. J Clin Oncol. 27:535–541. 2009. View Article : Google Scholar : PubMed/NCBI